143 related articles for article (PubMed ID: 2468797)
1. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.
Stamey TA; Kabalin JN; Ferrari M; Yang N
J Urol; 1989 May; 141(5):1088-90. PubMed ID: 2468797
[TBL] [Abstract][Full Text] [Related]
2. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Stamey TA; Kabalin JN; McNeal JE; Johnstone IM; Freiha F; Redwine EA; Yang N
J Urol; 1989 May; 141(5):1076-83. PubMed ID: 2468795
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.
Stamey TA; Kabalin JN; Ferrari M
J Urol; 1989 May; 141(5):1084-7. PubMed ID: 2468796
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.
Stamey TA; Kabalin JN
J Urol; 1989 May; 141(5):1070-5. PubMed ID: 2468794
[TBL] [Abstract][Full Text] [Related]
5. Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation).
Morgan WR; Zincke H; Rainwater LM; Myers RP; Klee GG
J Urol; 1991 Feb; 145(2):319-23. PubMed ID: 1703241
[TBL] [Abstract][Full Text] [Related]
6. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
Miller JI; Ahmann FR; Drach GW; Emerson SS; Bottaccini MR
J Urol; 1992 Mar; 147(3 Pt 2):956-61. PubMed ID: 1371568
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer.
Arai Y; Yoshiki T; Yoshida O
J Urol; 1990 Dec; 144(6):1415-9. PubMed ID: 1700155
[TBL] [Abstract][Full Text] [Related]
8. The value of serum prostate specific antigen determinations before and after radical prostatectomy.
Lange PH; Ercole CJ; Lightner DJ; Fraley EE; Vessella R
J Urol; 1989 Apr; 141(4):873-9. PubMed ID: 2467013
[TBL] [Abstract][Full Text] [Related]
9. The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate.
Maatman TJ
J Urol; 1989 Jun; 141(6):1378-80. PubMed ID: 2470927
[TBL] [Abstract][Full Text] [Related]
10. Hormonal management of advanced adenocarcinoma of the prostate.
Miles BJ
Henry Ford Hosp Med J; 1989; 37(1):16-8. PubMed ID: 2670839
[No Abstract] [Full Text] [Related]
11. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?
Leo ME; Bilhartz DL; Bergstralh EJ; Oesterling JE
J Urol; 1991 Apr; 145(4):802-6. PubMed ID: 1706440
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
13. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Holub S; Dürer A; Andert S; Haberl I; Theyer U; Hamilton G
Br J Cancer; 1997; 75(10):1515-8. PubMed ID: 9166947
[TBL] [Abstract][Full Text] [Related]
14. [Prostate antigen as a tumor marker of prostate cancer. (1) Changes of prostate antigen values during anti-androgen therapy].
Kuriyama M; Takeuchi T; Okano M; Fujimoto Y; Fujihiro S; Nishiura T; Murphy GP; Chu TM
Nihon Gan Chiryo Gakkai Shi; 1984 Aug; 19(7):1481-7. PubMed ID: 6084037
[No Abstract] [Full Text] [Related]
15. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
16. [Management of prostate cancer in Senegal: what is being done?].
Niang L; Ndoye M; Ouattara A; Jalloh M; Labou M; Thiam I; Kouka SC; Diaw JJ; Gueye SM
Prog Urol; 2013 Jan; 23(1):36-41. PubMed ID: 23287482
[TBL] [Abstract][Full Text] [Related]
17. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
18. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
19. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
Bayoumi AM; Brown AD; Garber AM
J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
